# Aerie Pharmaceuticals

Aerie Pharmaceuticals is an other based in Durham, United States.

## Overview

- **Organization type:** other
- **Headquarters:** Durham, United States
- **Region:** North America
- **Address:** Durham, NC, United States
- **Assets under management:** Undisclosed
- **Website:** www.aeriepharma.com
- **LinkedIn:** https://www.linkedin.com/company/aerie-pharmaceuticals-inc

## Regulatory record

- **Reports private funds:** No

## About

Alcon successfully completes its acquisition of Aerie Pharmaceuticals, expanding its ophthalmic pharmaceutical portfolio with Rocklatan and Rhopressa and adding significant R&D expertise in eye care.

## Sectors

- Healthcare Services

## People

- David Endicott — CEO of Alcon

## Questions

### What products did Aerie Pharmaceuticals develop?

Aerie developed Rocklatan (netarsudil and latanoprost ophthalmic solution) and Rhopressa (netarsudil ophthalmic solution) for glaucoma, both FDA-approved. Its pipeline included AR-15512, a Phase 3 candidate for dry eye disease (per Business Wire, 2023).

### How was Aerie Pharmaceuticals acquired?

Alcon completed the acquisition of Aerie in November 2023 for approximately $930 million in cash, funded with debt. The deal added Aerie's commercial products and R&D pipeline to Alcon's ophthalmic pharmaceutical division (per Business Wire, 2023).

## Related profiles

- [NextStar](https://altss.com/profile/nextstar)
- [EFC Systems Incorporated](https://altss.com/profile/efc-systems-incorporated)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/aerie-pharmaceuticals

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology